Abstract. Breast cancer is the most common cause of female cancer-associated mortality. Although treatment options, including chemotherapy, radiotherapy and surgery have led to a decline in the mortality rates associated with breast cancer, drug resistance remains one of the predominant causes for poor prognosis and high recurrence rates. The present study investigated the potential effects of the natural product, isorhamnetin on breast cancer, and examined the effects of isorhamnetin on the Akt/mammalian target of rapamycin (mTOR) and the mitogen-activated protein kinase (MAPK)/MAPK kinase (MEK) signaling cascades, which are two important signaling pathways for endocrine therapy resistance in breast cancer. The results of the present study indicate that isorhamnetin inhibits cell proliferation and induces cell apoptosis. In addition, isorhamnetin was observed to inhibit the Akt/mTOR and the MEK/extracellular signal-regulated kinase phosphorylation cascades. The inhibition of these two signaling pathways was attenuated by the two Akt and MEK1 inhibitors, but not by the nuclear factor-κB inhibitor. Furthermore, epidermal growth factor inhibited the effects of isorhamnetin via activation of the Akt and MEK signaling pathways. These results indicate that isorhamnetin exhibits antitumor effects in breast cancer, which are mediated by the Akt and MEK signaling pathways.
Introduction
Breast cancer is the most common type of malignant tumor in females (1-3). Despite major advances in breast cancer screening, early diagnosis and treatment modalities, it remains the predominant cause of cancer-associated mortality in females worldwide (4) . Existing treatment strategies include surgery, chemotherapy, endocrine therapy, and molecular-targeted therapy, which are limited by tumor recurrence and drug resistance (5) (6) (7) . Therefore, novel approaches to enhance the effects of therapeutic agents and improve the existing standards of care are urgently required.
It is well-known that the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and the mitogen-activated protein kinase (MAPK)/MAPK kinase (MEK) signaling pathways have important roles in tumor progression and drug resistance in various types of cancer (4) . Previous studies indicate that activation of the PI3K/Akt/mTOR signaling pathway is closely associated with the poor outcome of patients with breast cancer undergoing endocrine therapy (8, 9) . The activation of this signaling pathway had been identified as an important mechanism of tamoxifen resistance (10) (11) (12) (13) . The MEK/MAPK signaling pathway has also been associated with tamoxifen resistance and chemoresistance (14, 15) . In addition, the activation of the MEK/MAPK signaling pathway is involved in resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, in breast cancer cells (16) . Therefore, compounds targeting these signaling pathways are likely to be promising agents against endocrine therapy resistance in breast cancer.
Natural products are widely administered to prevent cancer in multi-stage carcinogenesis in humans, and have been the subject of intensive research in recent years (17) . Isorhamnetin is a flavonoid that is abundantly present in fruits, vegetables and tea, as well as in herbs that are used as traditional medicine, such as Ginkgo biloba extract and Persicaria thunbergii H (18, 19) . These two herbs are administered for the treatment of rheumatism, hemorrhage and cancer in traditional medicine (20) (21) (22) . Isorhamnetin is the active compound of these herbal medicinal plants, and is an immediate metabolite of quercetin, also termed 3'-O-methylquercetin, which has been shown to inhibit various types of cancer, including esophageal (23) and gastric cancer (24) , leukemia (25, 26) , skin (27) , colon (28) and lung cancer (29) . However, to the best of our knowledge, no study to date has focused on the inhibitory effects of isorhamnetin on breast cancer, and the molecular mechanisms underlying its effects remain unclear.
To better understand the mechanism underlying the effects of isorhamnetin on breast cancer, the present study examined the inhibition of isorhamnetin and the proliferation of various breast cancer cell lines, and explored the cell signaling pathways involved in its pharmacological effects. 3 cells/well in 100 µl DMEM and placed in cell incubator for 12 h at 37˚C in an atmosphere containing 5% CO 2 . The cells were then treated with various concentrations of isorhamnetin (100, 33.3, 11.1, 3.7, 1.2, 0.4 and 0 µM) for 48 h, and cell proliferation rates were determined by adding 10 µl CCK-8 solution (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) prior to incubation at 37˚C for 2 h. The absorbance was measured at a wavelength of 450 nm using a SpectraMax 190 Microplate Reader (Molecular Devices, LLC, Sunnyvale, CA, USA). For each assay, four parallel wells were included, and the half maximal inhibitory concentration (IC 50 ) was measured using the inhibition curve and presented as the mean of three independent experiments.
Materials and methods

Cell
Western blot analysis. The cells were washed twice with ice-cold phosphate-buffered saline (PBS) and harvested using radioimmunoprecipitation (RIPA) buffer (Beyotime Institute of Biotechnology; 50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 1% sodium deoxycholate, with protease and phosphatase inhibitors). The cell lysate was placed in RIPA for 30 min and centrifuged at a speed of 12,000 x g for 15 min, and the supernatant was then collected. Each aliquot of protein (10 µg) was separated by 12% SDS-PAGE and transferred to Hybond-C nitrocellulose membranes (GE Healthcare Biosciences, Pittsburg, PA, USA) in transfer buffer (192 mM glycine, 25 mM Tris, 2.5 mM SDS, and 10% methanol) (Sangon Biotech Co., Ltd., Shanghai, China). The membranes were blocked with 5% non-fat milk in Tris-buffered saline with 1% Tween-20 (TBST; Sangon . The protein expression levels were quantified by Image J, and presented as the relative expression levels to the control. (B) Isorhamnetin increased the expression level of Bax and cleaved caspase 3, and decreased the expression level of Bcl-2 and Bcl-xL (12-h treatment); (C) Isorhamnetin decreased the nuclear translocation of NF-κB (24-h treatment). p, phosphorylated; mTOR, mammalian target of rapamycin; MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal-regulated kinase; EGFR, epidermal growth factor receptor; PI3K, phosphoinositide 3-kinase; Bcl-2, B cell lymphoma 2; Bax, Bcl-2-associated protein X; Bcl-2-xL, Bcl-extra large; NF-κB, nuclear factor-κB. Statistical analysis. Protein expression was quantified using Image J software (version 1.31; Utrecht University, Utrecht, Netherlands) and expressed as the relative expression levels to the control group. P-values were calculated by comparison to the control group using analysis of variance with SPSS 19 (IBM SPSS, Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant result.
Results
Isorhamnetin inhibits proliferation and induces apoptosis of breast cancer cells.
The inhibitory effects of isorhamnetin on breast cancer cells were determined using the CCK-8 method. As shown in Fig. 1A , isorhamnetin inhibited the proliferation of numerous breast cancer cells (IC 50 , ~10 µM), including MCF7, T47D, BT474, BT-549, MDA-MB-231 and MDA-MB-468, whereas less inhibitory activity was observed in the MCF10A normal breast epithelial cell line (IC 50 , 38 µM). These results indicated that isorhamnetin induces pronounced inhibitory effects on breast cancer cell lines (P<0.05), as compared to normal breast epithelial cell lines, which suggests that isorhamnetin may act on the activation pathway of cancer cells. The effect of isorhamnetin on cell apoptosis was subsequently determined using two breast cancer cell lines, MCF7 and MDA-MB-468. Isorhamnetin markedly promoted cell apoptosis of the MCF7 and MDA-MB-468 cell lines (Fig. 1B) as shown by the sum of early and late apoptotic cells, with increased apoptotic rates observed in the MCF7 cells, as compared with the MDA-MD-468 cells; these results were consistent with the IC 50 values of isorhamnetin that were determined for the two cell lines.
Isorhamnetin inhibited the Akt/mTOR and MEK/ERK
signaling pathways, and promoted the activity of the mitochondrial apoptosis signaling pathway. In order to investigate the inhibitory mechanism underlying the effects of isorhamnetin on breast cancer cells, the PI3K/Akt/mTOR and MEK/ERK signaling pathways, which are closely associated with cell proliferation and survival, were examined. As shown in Fig. 2A , the phosphorylation levels of Akt and mTOR were markedly decreased by isorhamnetin, as well as the phosphorylation levels of MEK1/2 and ERK1/2 both in MCF7 and MDA-MB-468 cells; however, those of their upstream signaling molecules, such as phosphorylated EGFR and PI3K (110α) remained unchanged. The expression of the components of the cell apoptosis signaling pathway, including Bax, Bcl-2, Bcl-xL and cleaved caspase-3 were also investigated. Bax expression was induced by isorhamnetin, whereas the Bcl-2 expression level was markedly downregulated, and a marginal decrease was observed in the expression level of Bcl-xL (Fig. 2B) . Cleaved caspase-3 expression increased, implying that cell apoptosis was induced by isorhamnetin.
As isorhamnetin exhibits anti-oxidant effects, its impact on the downstream signaling molecule, NF-κB P65 was investigated, in order to identify whether these effects contributed to its anti-tumorigenic activity. As shown in Fig. 2C , the expression of cytosolic NF-κB P65 and its inhibitor, IκB were increased by isorhamnetin, whereas nuclear NF-κB P65 expression was decreased, suggesting that the nuclear translocation of NF-κB P65 is inhibited by isorhamnetin.
Inhibition of the Akt or MEK signaling pathways attenuates the effects of isorhamnetin.
Akt and MEK inhibitors (perifosine and PD184352) were used to elucidate the mechanism of action of isorhamnetin (whether it is via the Akt or MEK signaling pathways) on breast cancer (Fig. 3) . Perifosine is a potent pan-Akt inhibitor, which was used to block the Akt signaling pathway. Akt phosphorylation was inhibited by perifosine and partly inhibited by isorhamnetin (10 µM; Fig. 3A,) . Following pretreatment of the MCF7 cells with perifosine prior to the addition of isorhamnetin, induction of cell apoptosis was only marginally increased by isorhamnetin, as determined by cleaved caspase-3 and Annexin-V/PI dual staining (Fig. 3C ). These results demonstrate that blocking of Akt phosphorylation attenuated the effects of isorhamnetin.
Similarly, the MEK and ERK inhibitor, PD184352 was used to block the corresponding signaling pathways. As shown in Fig. 3B, PD184352 (1 µM) and isorhamnetin (10 µM) inhibited MEK1/2 phosphorylation and induced cell apoptosis. This was also determined by increased levels of cleaved caspase-3 expression and Annexin-V/PI dual staining (Fig. 3D) . MCF7 
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cells were pre-treated with PD184352 prior to the addition of isorhamnetin, and the induction of cell apoptosis was only marginally increased following treatment with isorhamnetin. These results demonstrate that inhibition of the MEK signaling pathway also attenuates the effects of isorhamnetin.
EGF reversed the inhibitory effects of isorhamnetin. EGF is a growth factor that binds to EGFR in order to induce the activation of downstream PI3K/Akt and MEK/ERK signaling pathways. Although EGFR phosphorylation did not change following treatment with isorhamnetin, the addition of EGF activated the Akt and MEK signaling pathways, and may be used to verify the effects of isorhamnetin. As shown in Fig. 4A , treatment with EGF markedly increased the phosphorylation levels of EGFR, Akt and MEK1/2, and these effects overrode the inhibitory effects of isorhamnetin on Akt and MEK1/2, thus inhibiting the cell apoptosis induced by isorhamnetin, as determined by decreased levels of cleaved caspase-3 expression.
NF-κB does not contribute to the induction of cell apoptosis by isorhamnetin.
The present study investigated whether the inhibition of NF-κB translocation contributed to cell apoptosis. An NF-κB inhibitor, JSH-23, was used to block the nuclear translocation of NF-κB, prior to treatment with isorhamnetin. As shown in Fig. 5 , treatment with JSH-23 inhibited NF-κB translocation, but did not result in the apoptosis of MCF7 cells, either alone or in combination with isorhamnetin (as demonstrated by cleaved caspase-3 and Annexin-V/PI dual staining). These results suggested that inhibition of the NF-κB signaling pathway does not contribute to the induction of cell apoptosis by isorhamnetin.
Discussion
The present study examined the inhibitory effects of isorhamnetin on breast cancer cell lines, and demonstrated that isorhamnetin inhibits the proliferation of various types of breast cancer cell, in ER-positive PR-positive HER2-negative cells (MCF7, T47D, BT474) and ER -PR -HER2 -cells (BT-549, MDA-MB-231, MDA-MB-468), but exhibited low inhibitory activity levels against normal MCF10A breast epithelial cells, suggesting that isorhamnetin inhibited breast cancer cells independently of ER and PR, and relies instead on activated cancer signaling pathways. Isorhamnetin also induced apoptosis in breast cancer cell lines. These results indicate that isorhamnetin may act as a novel natural compound for the prevention or treatment of breast cancer.
The molecular mechanisms underlying the observed anticancer effects of isorhamnetin were also investigated. Since the Akt/mTOR and MEK/ERK signaling pathways have important roles in breast cancer, they are closely associated with endocrine therapy resistance. Therefore, the effects of isorhamnetin on these signaling pathways were analyzed, demonstrating that isorhamnetin decreased the phosphorylation levels of Akt, mTOR, MEK1 and ERK1/2, but not those of EGFR. The results indicate that isorhamnetin may act on the Akt/mTOR and MEK/ERK signaling cascades, resulting in cell apoptosis, as demonstrated by the increase in levels of Bax, Bcl-2 and cleaved caspase-3 expression. The results of the present study are concordant with those of a previous study that demonstrated that isorhamnetin induces apoptosis via the inhibition of PI3K and MEK1 (27, 30) . A decrease in the phosphorylation levels of Akt and MEK1 was observed in the present study following pretreatment with their respective inhibitors (perifosine and PD184352). Furthermore, the inhibition of Akt and MEK was decreased by EGF, which induced activation of the PI3K/Akt/mTOR and MEK/ERK signaling pathways.
A previous study attributed the major chemopreventive mechanism of isorhamnetin to its antioxidant effects (31) . Therefore, the present study investigated whether NF-κB contributed to the antitumor activity of isorhamnetin in breast cancer. The results indicate that NF-κB did not contribute to the effects of isorhamnetin on cell apoptosis and, therefore, the proposed antioxidant activity may not explain the apoptotic effects of isorhamnetin on breast cancer, which may be associated instead with other effects, such as anti-inflammatory action. The antitumor activity of isorhamnetin may be different in various cancer types, such as in colon cancer, in which isorhamnetin has been shown to inhibit c-Src activation and β-catenin nuclear translocation (32) . In gastric cancer, isorhamnetin inhibits cell proliferation and invasion, and induces apoptosis through the modulation of the peroxisome proliferator-activated receptor γ activation signaling pathway (24) .
In conclusion, the results of the present study demonstrate that the antiproliferative and pro-apoptotic effects of isorhamnetin in breast cancer are mediated via inhibition of the Akt/mTOR and MEK/ERK signaling pathways, and provide a basis for pursuing the therapeutic significance and chemopreventive capabilities of isorhamnetin in breast cancer. Furthermore, isorhamnetin may be administered either alone or in combination with existing therapeutic strategies to enhance the treatment efficacy for breast cancer. However, the effects of isorhamnetin have yet to be investigated in humans, and hence further studies in humans are required prior to its clinical application to breast cancer treatment.
